Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2019 | Resonate: Ibrutinib associated with favourable PFS and OS in CLL

Susan O’Brien • 1 Jun 2019
ASCO 2019
Chronic Lymphocytic Leukemia
RESONATE RESONATE-2

Susan O’Brien, MD, of the University of California Irvine, Irvine, CA, discusses the results of the chronic lymphocytic leukemia (CLL)
RESONATE and RESONATE-2 study at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Susan O’Brien

Venetoclax and obinutuzumab combination therapy for CLL 2:03
Venetoclax and obinutuzumab combination therapy for CLL
Susan O’Brien • 14 Jun 2019
CAR T-cell therapy updates in CLL 2:19
CAR T-cell therapy updates in CLL
Susan O’Brien • 14 Jun 2019
CLL RESONATE-2: Five-year follow-up 2:00
CLL RESONATE-2: Five-year follow-up
Susan O’Brien • 13 Jun 2019
Zanubrutinib and acalabrutinib for CLL: potential alternatives to ibrutinib? 3:19
Zanubrutinib and acalabrutinib for CLL: potential alternatives to ibrutinib?
Susan O’Brien • 15 Jun 2019

Related Videos

Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study 3:24
Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study
Nirav Niranjan Shah • 24 Sep 2025
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines 1:56
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines
Nirav Niranjan Shah • 24 Sep 2025
BTK degraders in CLL: how may these agents shape the field? 1:30
BTK degraders in CLL: how may these agents shape the field?
Nirav Niranjan Shah • 24 Sep 2025
The importance of understanding the mechanisms underlying Richter’s transformation 1:15
The importance of understanding the mechanisms underlying Richter’s transformation
Gianluca Gaidano • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals